Blog

New York Startup, Quartet Health, Finds the Right Algorithm for Mental Health

Quartet Health wants to make mental health parity a reality.

Doctors have access to all sorts of historical patient records, which help them make diagnoses and referrals. Now they are gaining access to a technology platform that analyzes all of that data to learn if the patient’s physiological symptoms are likely to be associated with―and possibly exacerbated by―a simultaneous mental health condition.

In the medical world, this is called comorbidity. For New York-based startup Quartet Health, it might soon be called a goldmine.

Quartet was launched in early 2014 by Arun Gupta, who at the time was working as a healthcare-focused private equity investor. What he saw was that behavioral health issues kept coming up at some of his firm’s portfolio companies, and that the discipline was rarely being addressed by applying basic technologies. At the same time, Gupta also was serving as an advisor to Palantir Technologies, a secretive Silicon Valley company known for applying big data analytics to seemingly intractable problems.

 

Read More

Steward ACO Picks Quartet Health for Behavioral Health IT

Steward Health Care Network, the second largest physician network in Massachusetts, will offer Quartet Health’s platform as a service to its providers and their patients.

The multi-year agreement expands the partnership between Steward and Quartet Health that started in 2015.

Boston-based Steward Health Care, a Next Generation ACO,  is the largest integrated community care organization and hospital network in New England, with more than 17,000 employees in more than 150 communities.

Former Rhode Island Congressman Patrick Kennedy joined the board of the New York-based startup last October.

Read More

USHealthVest’s Chicago Behavioral Hospital launches center for veterans’ mental health

Des Plaines, Illinois, January 15, 2016 – Chicago Behavioral Hospital, owned by USHealthvest, has opened Extra Mile Veteran Care™, the first specialized private outpatient program in Cook County to be operated by military veteran health practitioners, to address the unique mental health and chemical dependency needs of veterans and their families. More than 700,000 veterans of all generations live in Illinois and more than 25 percent reside in Cook County.

The Extra Mile Veteran Care™ leadership and clinical team, primarily veterans from all foreign wars, focus on evidence-based practices to understand and address mental health and addiction needs. Numerous studies affirm that evidence-based interventions such as cognitive behavioral therapy, mentoring, motivational enhancement therapy, trauma-focused therapy and wellness programs often work best for veterans with mental health and addiction problems.

 

Read More

TraceLink Announces NEXUS ’16: Mastering Global Traceability with a Digital Supply Chain Network

TraceLink Inc., the world’s largest track and trace network for connecting the Life Sciences supply chain and eliminating counterfeit prescription drugs from the global marketplace, today announced NEXUS ’16—the company’s annual gathering of business leaders and pharmaceutical supply chain professionals dedicated to shaping the future of global drug traceability for Life Sciences. The two-day event will be held on October 19 and 20, at the Revere Hotel Boston, with a special evening event at the John F. Kennedy Presidential Library & Museum. Registration for NEXUS ’16 is now open, with early purchase discounts available for all tickets sales before June 1, 2016.

 

Read More

Aclaris Therapeutics Initiates Phase 3 Clinical Trials Of A-101 For The Treatment Of Seborrheic Keratosis

Aclaris Therapeutics, Inc. (NASDAQ:ACRS), today announced the initiation of two Phase 3 clinical trials to evaluate A-101 Topical Solution for the treatment of seborrheic keratosis (SK).

The two Phase 3 clinical trials will evaluate the safety and efficacy of A-101 Topical Solution compared with a vehicle solution (placebo).  Approximately 800 subjects will be randomized in these multi-center, double-blinded, vehicle-controlled, clinical trials, which are being conducted at 34 investigational centers within the United States.

“The initiation of the Phase 3 program for A-101 Topical Solution is an important milestone in our development program and follows the positive Phase 2 clinical results and an End-of-Phase 2 meeting with the FDA,” said Christopher Powala, Chief Operating Officer of Aclaris. “Our goal is to offer a new treatment option for patients and physicians to treat SK lesions, a condition for which there are currently no FDA-approved drugs.”

 

Read More

TraceLink Boosts Leadership Position as Proven Track and Trace Network Exceeds 200,000

TraceLink Inc., the world’s largest track and trace network for connecting the Life Sciences supply chain and eliminating counterfeit prescription drugs from the global marketplace, today announced that its Life Sciences Cloud has exceeded more than 200,000 connected members across the global pharmaceutical supply chain. A single connection to the Life Sciences Cloud allows pharmaceutical manufacturers, CMOs, distributors and dispensers of any size to connect with any trading partner that is already configured on the network and instantly begin sharing documents and data for regulatory compliance. In addition, the company’s 15 commercially available drug traceability solutions are now used by pharmaceutical suppliers in global markets that comprise 75 percent of the world’s drug supply.

“The unique approach we’ve taken with our network model is what sets TraceLink apart, and continues to fuel our success,” said Shabbir Dahod, president and CEO of TraceLink. “Other vendors suggest that on premise systems and single-tenant architectures can address the complex compliance challenges facing the industry, but the reality is that these approaches just can’t scale to meet the serialization processing and data exchange demands of the new regulatory laws. Our track and trace network is proven to accelerate the ability for any pharmaceutical manufacturer, distributor or dispenser to achieve regulatory compliance with the least cost, time and risk—which is why we’ve been able to grow our network from a few thousand suppliers to more than 200,000 in a little over a year.”

 

Read More

Liazon Named Winner Of Fall 2015 Digital Health Awards

Liazon, operator of the industry-leading private benefits exchange for businesses across the U.S., was named a winner of the Fall 2015 Digital Health Awards. Liazon’s flagship product, the Bright Choices® Exchange, received an award in the “Portal” category, making this the fourth consecutive Digital Health Award the exchange has received. The awards, which are run by the Health Information Resource Center, recognize the nation’s best digital health resources.

Bright Choices helps employers save money on their health care costs by setting predictable budgets while allowing employees to personalize their benefits package with a selection of health, dental, vision, life, disability, and other benefits from top national and regional providers.

 

Read More

Surface Oncology Partners with Novartis in $170M Deal to Pursue Next-Gen Cancer Immunotherapies

Fledgling Cambridge, MA-based startup Surface Oncology has pulled off its first Big Pharma deal, grabbing $170 million in near-term milestones, an upfront and research support from Novartis ($NVS) as it pursues next-gen cancer immuno-therapies.

In exchange, Novartis is buying a ringside seat to Surface Oncology’s pipeline activities, taking worldwide rights to the lead program and dibs on three more cancer programs. Surface, though, isn’t just signing away rights. It’s keeping U.S. commercialization rights on at least half of the programs. And there’s more cash available in unspecified milestones in the deal.

“The total deal potential is consistent with other major IO deals in the space such as the recent Symphogen deal, among others,” says CEO Detlev Biniszkiewicz in an email response to FierceBiotech. “We will receive major clinical and commercial milestones for all four programs as well as double digit royalties. The total deal potential reflects the value of Surface’s novel portfolio of projects that target regulatory T cell and macrophage populations, inhibitory cytokines, and immunosuppressive metabolites.”

Read More

Ironwood Pharmaceuticals Details Strategy To Build Top-Performing Commercial Biotechnology Company

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today detailed its strategy to build a top-performing commercial biotechnology company generating rapid, sustainable, high-margin growth. As part of this strategy, the Company outlined three- and five-year operational and financial goals, which include bringing new medicines to market, advancing several blockbuster opportunities into later-stage clinical development, and generating growing cash flows. These goals do not include the potential upside impact of any acquisitions, licensing or other corporate development transactions.

“Ironwood is one of the few companies in the biopharmaceutical industry to have successfully discovered, developed and commercialized a product that has become the branded prescription market leader in its category,” said Peter Hecht, chief executive officer of Ironwood. “Our flagship product LINZESS is well on its way to becoming our first blockbuster: in just its third year on the market, it generated approximately $450 million in 2015 U.S. net sales, annual growth of more than 50%, and is delivering rapidly expanding commercial margins. We are advancing potential blockbuster products for IBS-C/CIC, vascular/fibrotic diseases, and refractory GERD, and we believe the growing contribution from our commercial business and cash on hand are sufficient to fully fund our core business without the need to raise additional capital.”

 

Read More

Procured Health Reports Significant Growth in 2015

Procured Health (Procured) announced today that it achieved record growth in 2015. The four-year-old, Chicago-based company noted that the healthcare industry’s shift towards value-based care and bundled payments was a key driver of its success, and will continue to be in 2016, as more hospitals prepare for the challenges of new payment models based on cost, quality, and outcomes. Procured’s technology-driven solutions empower the buyers and users of medical products to make optimal decisions. Health systems leveraging Procured’s platform have eliminated substantial costs while also improving clinical outcomes.

Clinical supplies, including physician preference items (PPIs), represent the second largest and fastest growing cost category for hospitals. Uninformed decisions in this realm will account for more than $35 billion in wasteful spending in 2016. These wasted dollars are noteworthy not only because they have been largely ignored by most hospitals until now, but also because pursuing evidenced-based savings initiatives in the supply chain impacts quality and patient care—not just the bottom line.

 

Read More